Stockreport

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Merus N.V. - Common Shares  (MRUS) 
Last merus n.v. - common shares earnings: 8/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/mrus
PDF UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage [Read more]